Frantisek Tousek
Overview
Explore the profile of Frantisek Tousek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hromadka M, Motovska Z, Hlinomaz O, Kala P, Varvarovsky I, Dusek J, et al.
J Cardiol
. 2021 Dec;
79(5):626-633.
PMID: 34924237
Objectives: Based on previous studies with clopidogrel, the time between acute myocardial infarction (AMI) symptoms onset and primary percutaneous coronary intervention (PCI) was proven as important prognostic factor. Our aim...
2.
Hlinomaz O, Motovska Z, Knot J, Miklik R, Sabbah M, Hromadka M, et al.
J Clin Med
. 2021 Nov;
10(21).
PMID: 34768623
Drug-eluting stents (DES) are the recommended stents for primary percutaneous coronary intervention (PCI). This study aimed to determine why interventional cardiologists used non-DES and how it influenced patient prognoses. The...
3.
Hromadka M, Motovska Z, Hlinomaz O, Kala P, Tousek F, Jarkovsky J, et al.
J Pers Med
. 2021 Jul;
11(6).
PMID: 34199723
This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI)....
4.
Simek S, Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, et al.
J Clin Med
. 2020 Aug;
9(8).
PMID: 32781780
Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of...
5.
Dusek J, Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, et al.
Int J Cardiol
. 2020 Jul;
319:1-6.
PMID: 32634499
Background: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. Methods And Results: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity...
6.
Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, et al.
J Am Coll Cardiol
. 2017 Nov;
71(4):371-381.
PMID: 29154813
Background: Early outcomes of patients in the PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any significant differences between 2 potent...
7.
Staskova K, Bulava A, Tesarik R, Tousek F
Vnitr Lek
. 2017 Apr;
63(3):163-169.
PMID: 28379017
Introduction: Radiofrequency catheter ablation (RFA) has recently become a routine part of atrial fibrillation (AF) treatment. The goal of our study was to determine whether the implementation of RFA of...
8.
Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J, et al.
Circulation
. 2016 Sep;
134(21):1603-1612.
PMID: 27576777
Background: No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y inhibitors...
9.
Tousek P, Tousek F, Horak D, Cervinka P, Rokyta R, Pesl L, et al.
Int J Cardiol
. 2014 Mar;
173(2):204-8.
PMID: 24602321
Background: The incidence and treatment strategies of acute coronary syndrome (ACS) vary by region. Additionally, the clinical spectrum of ACS is changing and outcomes are improving. Aim: We assessed the...
10.
Bhatt D, Stone G, Mahaffey K, Gibson C, Steg P, Hamm C, et al.
N Engl J Med
. 2013 Mar;
368(14):1303-13.
PMID: 23473369
Background: The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts...